ArticleJAMA health forum2022
Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.
Article in JAMA health forum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements.The Milbank quarterly · 2026Article
- Buprenorphine utilization following removal of prior authorization requirements in the Kentucky Medicaid population.Drug and alcohol dependence · 2026Article
- State Prior Authorization Prohibitions and Buprenorphine Retention Among Privately Insured Patients.JAMA health forum · 2026Article
- Pharmacoepidemiology of Oxycodone in the USA: An Observational Study of ARCOS, Medicaid, and Medicare Drug Databases.Pharmacology research & perspectives · 2026Observational
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015-23.Health affairs (Project Hope) · 2025Article
- Medicaid prescription cap policies and exemptions for medications for opioid use disorder: A process and content analysis.Health affairs scholar · 2025Article
- How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States.The Milbank quarterly · 2025Article
- Predictors of Medicaid managed care plan performance on opioid use disorder treatment quality metrics.Drug and alcohol dependence · 2025Article
- Identifying and responding to policy-related barriers, facilitators, and misunderstandings in the HEALing communities study: A community-driven approach.The International journal on drug policy · 2025Article
- Assessing inequities in buprenorphine treatment across the care cascade.Drug and alcohol dependence · 2025Observational
- Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl.Addiction science & clinical practice · 2025Article
- Medicaid managed care restrictions on medications for the treatment of opioid use disorder.Health services research · 2025Article
- State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.Substance use & misuse · 2025Article
- Trends in Opioid Use Disorder in the Veterans Health Administration, 2005-2022.JAMA network open · 2024Article
- US payment policy for medications to treat opioid use disorder: landscape and opportunities.Health affairs scholar · 2024Article
- A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.BMC health services research · 2024Article
- 2024 US-China Round Table Consensus Discussion on Perioperative Opioid Management.Translational perioperative and pain medicine · 2024Article
- Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018.Health affairs (Project Hope) · 2024Article
- Prescriptions for Buprenorphine in Michigan Following an Education Intervention.JAMA network open · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: State Medicaid programs have implemented initiatives to expand treatment coverage for opioid use disorder (OUD); however, some Medicaid programs still require prior authorizations (PAs) for filling buprenorphine prescriptions. Objective: To evaluate the changes in buprenorphine use for OUD among Medicaid enrollees in states that completely removed buprenorphine PA requirements. Design Setting and Participants: This retrospective cross-sectional study analyzed the immediate and trend changes on buprenorphine use during 2013 to 2020 associated with removal of PA requirements using a controlled interrupted time series analysis to account for autocorrelation. Data were collected from Medicaid State Drug Utilization Data for 2 states (California and Illinois) that completely removed a buprenorphine PA during the study period, and buprenorphine prescriptions for OUD treatment were identified among Medicaid enrollees. Main Outcomes and Measures: Quarterly total number of buprenorphine prescriptions for each state was calculated, and stratification analyses were conducted by dosage form (films and tablets). Results: Among the 2 state Medicaid programs (California and Illinois) that removed buprenorphine PAs, there was a total of 702 643 and 415 115 eligible buprenorphine prescription claims, respectively. After removing PA requirements for buprenorphine, there was an immediate increase that was not statistically significant (rate ratio [RR], 1.11; 95% CI, 0.76-1.61) in the number of all buprenorphine prescriptions in California and a statistically significant increase (RR, 6.99; 95% CI, 4.67-10.47) in the number of all buprenorphine prescriptions in Illinois relative to the change in the control states (Alabama, Florida, Idaho, Kansas, Mississippi, Nevada, South Dakota, and Wyoming). Additionally, there was a statistically significant decreasing trend in the number of all buprenorphine prescriptions in California (RR, 0.88; 95% CI, 0.82-0.94) and a statistically significant increasing trend in Illinois (RR, 1.11; 95% CI, 1.05-1.19) relative to the trend in control states. Conclusions and Relevance: In this cross-sectional study, removal of buprenorphine PA requirements was associated with a statistically significant increase in the number of buprenorphine prescription fills among Medicaid populations in 1 of the 2 included states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.